ECSP024369A - S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares - Google Patents
S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y ocularesInfo
- Publication number
- ECSP024369A ECSP024369A EC2002004369A ECSP024369A ECSP024369A EC SP024369 A ECSP024369 A EC SP024369A EC 2002004369 A EC2002004369 A EC 2002004369A EC SP024369 A ECSP024369 A EC SP024369A EC SP024369 A ECSP024369 A EC SP024369A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- disorder
- dementias
- treatment
- behavioral
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title 1
- 229960000607 ziprasidone Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 206010012289 Dementia Diseases 0.000 abstract 4
- 208000028017 Psychotic disease Diseases 0.000 abstract 3
- 230000003542 behavioural effect Effects 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- NHUDBVVEHOSVCD-UHFFFAOYSA-N 6-chloro-5-[2-[4-(2-methylsulfanylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound CSC1=CC=CC=C1C(=N)N1CCN(CCC=2C(=CC=3NC(=O)CC=3C=2)Cl)CC1 NHUDBVVEHOSVCD-UHFFFAOYSA-N 0.000 abstract 1
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 206010014557 Emotional poverty Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010041243 Social avoidant behaviour Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Esta invención se refiere a composiciones farmacéuticas que contienen S-metil-dihidro-ziprasidona y al uso de dicho compuesto y de sus sales farmacéuticamente aceptables para el tratamiento de trastornos psiquiátricos y oculares. De una manera más específica, se refiere al uso de dicho compuesto y de sus sales farmacéuticamente aceptables para el tratamiento de un trastorno o afección seleccionado de: esquizofrenia, trastornos de ansiedad como el trastorno de ansiedad generalizada, trastorno de pánico, trastorno de estrés postraumático y fobias ( por ejemplo, fobia social, agorafobia, etc.); episodio psicóticos de ansiedad, agitación, agresividad excesiva, tensión, o retraimiento social o emocional asociados con psicosis; trastornos del estado de ánimo pisicóticos como el trastorno depresivo mayor grave; trastornos del estado de ánimo asociados con trastornos psicóticos como la manía aguda y la depresión asociadas con trastornos bipolares, y trastornos del estado de ánimo asociados con esquizofrenia; desviaciones del comportamiento asociadas con retraso mental, trastornos de autismo y trastornos de la conducta; demencias como las demencias asociadas con retraso mental, trastornos de autismo y trastornos de la conducta; demencias como las demencias asociadas con la enfermedad de Alzeheimer; discinesias inducidas por drogas y de base neurodegenerativa; trastorno obsesivo compulsivo; síndrome de Tourette; glaucoma, y retinopatía isquémica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20913600P | 2000-06-02 | 2000-06-02 | |
| US21217200P | 2000-06-16 | 2000-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024369A true ECSP024369A (es) | 2003-02-06 |
Family
ID=26903852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2002004369A ECSP024369A (es) | 2000-06-02 | 2002-11-29 | S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares |
Country Status (44)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003296991A1 (en) | 2002-12-13 | 2004-07-09 | Regents Of The University Of Minnesota | Scleral depressor |
| WO2005040160A2 (en) | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
| JP2012174228A (ja) * | 2011-02-24 | 2012-09-10 | Kyocera Corp | プログラム保護装置および通信装置 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| ATE236902T1 (de) * | 1996-05-07 | 2003-04-15 | Pfizer | Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist |
| ATE247963T1 (de) * | 1998-05-26 | 2003-09-15 | Pfizer Prod Inc | Medikament zur behandlung von glaukoma und ischämischer retinopathie |
| WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
-
2001
- 2001-05-28 EP EP06116051A patent/EP1698338B1/en not_active Expired - Lifetime
- 2001-05-28 IL IL15278201A patent/IL152782A0/xx active IP Right Grant
- 2001-05-28 JP JP2001587771A patent/JP2003534381A/ja not_active Withdrawn
- 2001-05-28 ES ES04013380T patent/ES2277170T3/es not_active Expired - Lifetime
- 2001-05-28 PT PT06116051T patent/PT1698338E/pt unknown
- 2001-05-28 DE DE60133596T patent/DE60133596D1/de not_active Expired - Lifetime
- 2001-05-28 AT AT06116051T patent/ATE391507T1/de not_active IP Right Cessation
- 2001-05-28 WO PCT/IB2001/000933 patent/WO2001091756A2/en not_active Ceased
- 2001-05-28 EA EA200201168A patent/EA007068B1/ru not_active IP Right Cessation
- 2001-05-28 GE GE4972A patent/GEP20053512B/en unknown
- 2001-05-28 EP EP01932011A patent/EP1286672B1/en not_active Expired - Lifetime
- 2001-05-28 SI SI200130681T patent/SI1468686T1/sl unknown
- 2001-05-28 DE DE60124093T patent/DE60124093D1/de not_active Expired - Lifetime
- 2001-05-28 CN CN01810620A patent/CN1431901A/zh active Pending
- 2001-05-28 DE DE60124791T patent/DE60124791T2/de not_active Expired - Fee Related
- 2001-05-28 YU YU90702A patent/YU90702A/sh unknown
- 2001-05-28 KR KR1020027016364A patent/KR20030007824A/ko not_active Ceased
- 2001-05-28 CZ CZ20023860A patent/CZ20023860A3/cs unknown
- 2001-05-28 DK DK04013380T patent/DK1468686T3/da active
- 2001-05-28 OA OA1200200349A patent/OA12267A/en unknown
- 2001-05-28 AT AT01932011T patent/ATE343387T1/de not_active IP Right Cessation
- 2001-05-28 NZ NZ551012A patent/NZ551012A/en unknown
- 2001-05-28 AU AU2001258690A patent/AU2001258690A1/en not_active Abandoned
- 2001-05-28 PT PT04013380T patent/PT1468686E/pt unknown
- 2001-05-28 PL PL01365576A patent/PL365576A1/xx unknown
- 2001-05-28 HR HR20020953A patent/HRP20020953A2/hr not_active Application Discontinuation
- 2001-05-28 CA CA002410618A patent/CA2410618A1/en not_active Abandoned
- 2001-05-28 BR BR0111271-6A patent/BR0111271A/pt not_active Application Discontinuation
- 2001-05-28 HU HU0301747A patent/HUP0301747A2/hu unknown
- 2001-05-28 EP EP04013380A patent/EP1468686B1/en not_active Expired - Lifetime
- 2001-05-28 EE EEP200200670A patent/EE200200670A/xx unknown
- 2001-05-28 SK SK1662-2002A patent/SK16622002A3/sk not_active Application Discontinuation
- 2001-05-28 AT AT04013380T patent/ATE345818T1/de not_active IP Right Cessation
- 2001-05-28 MX MXPA02011862A patent/MXPA02011862A/es active IP Right Grant
- 2001-05-28 UA UA2002119557A patent/UA79425C2/uk unknown
- 2001-05-31 AP AP2005003272A patent/AP1747A/xx active
- 2001-05-31 HN HN2001000119A patent/HN2001000119A/es unknown
- 2001-05-31 UY UY26742A patent/UY26742A1/es not_active Application Discontinuation
- 2001-05-31 PE PE2001000504A patent/PE20011329A1/es not_active Application Discontinuation
- 2001-05-31 AP APAP/P/2001/002180A patent/AP1831A/en active
- 2001-05-31 DO DO2001000181A patent/DOP2001000181A/es unknown
- 2001-06-01 SV SV2001000473A patent/SV2002000473A/es not_active Application Discontinuation
- 2001-06-01 AR ARP010102641A patent/AR028937A1/es unknown
- 2001-06-01 PA PA20018518301A patent/PA8518301A1/es unknown
- 2001-06-04 US US09/873,973 patent/US20060287336A1/en not_active Abandoned
-
2002
- 2002-11-11 IL IL152782A patent/IL152782A/en not_active IP Right Cessation
- 2002-11-12 BG BG107267A patent/BG107267A/bg unknown
- 2002-11-14 IS IS6619A patent/IS6619A/is unknown
- 2002-11-28 ZA ZA200209665A patent/ZA200209665B/en unknown
- 2002-11-29 NO NO20025760A patent/NO325077B1/no unknown
- 2002-11-29 EC EC2002004369A patent/ECSP024369A/es unknown
- 2002-11-29 MA MA26927A patent/MA26908A1/fr unknown
-
2007
- 2007-02-08 CY CY20071100161T patent/CY1105992T1/el unknown
- 2007-11-14 JP JP2007296039A patent/JP2008056700A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088593A (es) | 5-(arilsulfonil)-pirazolopiperidinas | |
| AR002289A1 (es) | Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias. | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| CR11095A (es) | Compuestos amino-heterociclicos | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| BRPI0406879A (pt) | Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos | |
| UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
| ES2119124T3 (es) | Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso. | |
| ES2183583T3 (es) | Agente con efecto antidepresivo, que contiene pramipexol y sertralina. | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| AR045004A1 (es) | Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| ES2523518T3 (es) | Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias | |
| BRPI0721113A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios | |
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| AR028705A1 (es) | Bis-arilsulfonas | |
| ECSP024369A (es) | S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| UY29924A1 (es) | Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables | |
| AR035915A1 (es) | Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar | |
| GT200200275A (es) | Derivados de ester del acido pirrolidina-2-carboxilico | |
| UY28401A1 (es) | Metabolito | |
| AR049343A1 (es) | Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos | |
| TH84255B (th) | S-เมทธิล-ไดไฮโดร-ซิปราสิโดนสำหรับรักษาความผิดปกติทางจิตเวช และความผิดปกติของตา | |
| AR056056A1 (es) | Asociacion entre la agomelatina y un inhibidor de la recaptacion de la noradrenalina y las composiciones farmaceuticas que las contienen |